Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
Immunotherapy represents a groundbreaking therapeutic approach, based on the immune system’s intrinsic capacity to interfere with tumor progression, that opens the horizons in the treatment of endometrial cancer. However, the clinical efficacy of immunotherapy is hampered by the development of resis...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1523518/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593922658926592 |
|---|---|
| author | Liubov A. Tashireva Irina V. Larionova Irina V. Larionova Nikita A. Ermak Anastasia A. Maltseva Ekaterina I. Livanos Anna Yu. Kalinchuk Marina N. Stakheyeva Larisa A. Kolomiets |
| author_facet | Liubov A. Tashireva Irina V. Larionova Irina V. Larionova Nikita A. Ermak Anastasia A. Maltseva Ekaterina I. Livanos Anna Yu. Kalinchuk Marina N. Stakheyeva Larisa A. Kolomiets |
| author_sort | Liubov A. Tashireva |
| collection | DOAJ |
| description | Immunotherapy represents a groundbreaking therapeutic approach, based on the immune system’s intrinsic capacity to interfere with tumor progression, that opens the horizons in the treatment of endometrial cancer. However, the clinical efficacy of immunotherapy is hampered by the development of resistance in patients. The resistance to immunotherapy is multifactorial mechanism, encompassed genetic and epigenetic alterations in tumor cells modulating immune checkpoint molecules, resulted in escaping immune surveillance. The tumor microenvironment can orchestrate an immunosuppressive milieu, attenuating the immune response and facilitating tumor progression. To overcome immunotherapeutic resistance in endometrial cancer we must bring to light the mechanisms of intricate interplay between neoplastic cells, the host immune system, and the tumor microenvironment. The identification of predictive biomarkers for immunotherapeutic response and the innovative agents capable of reversing resistance pathways must be developed. Our review summarizes accumulated data on the role of cells of the tumor microenvironment and their regulatory molecules in the mechanisms underlying therapeutic effects of immune checkpoint inhibitors, including resistance to therapy. Major question we raise here – which group of patients is the most favorable to achieve durable immunotherapy response in endometrial cancer? |
| format | Article |
| id | doaj-art-4eb0eee58f0f4cdd9e0a67c6146fa057 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-4eb0eee58f0f4cdd9e0a67c6146fa0572025-01-20T07:20:15ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15235181523518Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironmentLiubov A. Tashireva0Irina V. Larionova1Irina V. Larionova2Nikita A. Ermak3Anastasia A. Maltseva4Ekaterina I. Livanos5Anna Yu. Kalinchuk6Marina N. Stakheyeva7Larisa A. Kolomiets8Laboratory of Molecular Therapy of Cancer, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RussiaLaboratory of Molecular Therapy of Cancer, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RussiaLaboratory of Translational Cellular and Molecular Biomedicine, National Research Tomsk State University, Tomsk, RussiaLaboratory of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RussiaDepartment of Gynecology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RussiaLaboratory of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RussiaLaboratory of Molecular Therapy of Cancer, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RussiaLaboratory of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RussiaDepartment of Gynecology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RussiaImmunotherapy represents a groundbreaking therapeutic approach, based on the immune system’s intrinsic capacity to interfere with tumor progression, that opens the horizons in the treatment of endometrial cancer. However, the clinical efficacy of immunotherapy is hampered by the development of resistance in patients. The resistance to immunotherapy is multifactorial mechanism, encompassed genetic and epigenetic alterations in tumor cells modulating immune checkpoint molecules, resulted in escaping immune surveillance. The tumor microenvironment can orchestrate an immunosuppressive milieu, attenuating the immune response and facilitating tumor progression. To overcome immunotherapeutic resistance in endometrial cancer we must bring to light the mechanisms of intricate interplay between neoplastic cells, the host immune system, and the tumor microenvironment. The identification of predictive biomarkers for immunotherapeutic response and the innovative agents capable of reversing resistance pathways must be developed. Our review summarizes accumulated data on the role of cells of the tumor microenvironment and their regulatory molecules in the mechanisms underlying therapeutic effects of immune checkpoint inhibitors, including resistance to therapy. Major question we raise here – which group of patients is the most favorable to achieve durable immunotherapy response in endometrial cancer?https://www.frontiersin.org/articles/10.3389/fimmu.2024.1523518/fullendometrial cancerimmunotherapyimmune checkpoint inhibitorstumor microenvironmentpredictive biomarkers |
| spellingShingle | Liubov A. Tashireva Irina V. Larionova Irina V. Larionova Nikita A. Ermak Anastasia A. Maltseva Ekaterina I. Livanos Anna Yu. Kalinchuk Marina N. Stakheyeva Larisa A. Kolomiets Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment Frontiers in Immunology endometrial cancer immunotherapy immune checkpoint inhibitors tumor microenvironment predictive biomarkers |
| title | Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment |
| title_full | Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment |
| title_fullStr | Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment |
| title_full_unstemmed | Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment |
| title_short | Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment |
| title_sort | predicting immunotherapy efficacy in endometrial cancer focus on the tumor microenvironment |
| topic | endometrial cancer immunotherapy immune checkpoint inhibitors tumor microenvironment predictive biomarkers |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1523518/full |
| work_keys_str_mv | AT liubovatashireva predictingimmunotherapyefficacyinendometrialcancerfocusonthetumormicroenvironment AT irinavlarionova predictingimmunotherapyefficacyinendometrialcancerfocusonthetumormicroenvironment AT irinavlarionova predictingimmunotherapyefficacyinendometrialcancerfocusonthetumormicroenvironment AT nikitaaermak predictingimmunotherapyefficacyinendometrialcancerfocusonthetumormicroenvironment AT anastasiaamaltseva predictingimmunotherapyefficacyinendometrialcancerfocusonthetumormicroenvironment AT ekaterinailivanos predictingimmunotherapyefficacyinendometrialcancerfocusonthetumormicroenvironment AT annayukalinchuk predictingimmunotherapyefficacyinendometrialcancerfocusonthetumormicroenvironment AT marinanstakheyeva predictingimmunotherapyefficacyinendometrialcancerfocusonthetumormicroenvironment AT larisaakolomiets predictingimmunotherapyefficacyinendometrialcancerfocusonthetumormicroenvironment |